Author:
Mayer Ruth J.,Callahan James F.
Subject
Drug Discovery,Pharmacology,Molecular Medicine
Reference39 articles.
1. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis;Lee;Nature,1994
2. Polmar, S.H. et al. (2002) Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB-796 BS) administered twice daily for 14 days to healthy volunteers. AAAAI 58th Annual Meeting (Abstract #157)
3. Gupta, A. et al. (2002) Safety, pharmacokinetics and pharmacodynamics of single doses or an oral p38 MAP kinase inhibitor (BIRB-796 BS) in healthy human males a placebo-controlled, randomized study, double-blinded at each dose level. AAAAI 58th Annual Meeting (Abstract #158)
4. Weisman, M. et al. (2002) A double-blind, placebo controlled trial of VX-745, an oral p38 mitogen-activated protein kinase (MAPK) inhibitor in patients with rheumatoid arthritis (RA). 2002 Annual European Congress of Rheumatology, Stockholm, Sweden (Abstract FRI0018)
5. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38 alpha protein;Lee;Curr. Med. Chem.,2005
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献